Price T Rowe Associates Inc. MD Cuts Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Price T Rowe Associates Inc. MD cut its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 33.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,394,306 shares of the company's stock after selling 690,381 shares during the quarter. Price T Rowe Associates Inc. MD owned about 2.44% of Structure Therapeutics worth $37,814,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. ANTIPODES PARTNERS Ltd increased its position in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares during the period. GAMMA Investing LLC raised its stake in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after purchasing an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth $40,000. Assetmark Inc. grew its position in Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after buying an additional 953 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Structure Therapeutics by 673.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after buying an additional 3,549 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Price Performance

GPCR stock traded down $0.24 during midday trading on Friday, hitting $27.09. The stock had a trading volume of 739,761 shares, compared to its average volume of 920,944. The company's 50-day moving average price is $20.52 and its 200 day moving average price is $27.46. The firm has a market cap of $1.55 billion, a PE ratio of -36.61 and a beta of -1.35. Structure Therapeutics Inc. has a 12-month low of $13.22 and a 12-month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on GPCR shares. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Stifel Nicolaus initiated coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. William Blair initiated coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, Citigroup assumed coverage on Structure Therapeutics in a report on Friday. They set a "buy" rating and a $60.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $78.63.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.